HC Wainwright Maintains Neutral Rating for Inovio Pharmaceuticals

Recently, analysts from HC Wainwright reaffirmed a "neutral" rating for Inovio Pharmaceuticals (NASDAQ:INO) in their latest report to investors. They have set a target price of $3.00 for the company's stock. This target suggests a promising potential upside of approximately 42.86% from Inovio's current market price.

Inovio Pharmaceuticals shares opened at $2.10 on Wednesday. The company has seen its stock fluctuate within a 52-week range, with a low of $1.74 and a high of $14.75. Currently, the market capitalization of Inovio Pharmaceuticals stands at $54.81 million. The company has a negative price-to-earnings ratio of -1.00 and a beta value of 0.92, signaling lower volatility than the broader market. The 50-day moving average price for the stock is $2.05, while the two-hundred day moving average is $3.77.

Other Ratings and Analysts' Opinions

Inovio Pharmaceuticals has received mixed reviews from financial analysts. On January 10th, JMP Securities also issued a report, maintaining a "market outperform" rating and setting an ambitious target price of $18.00 for the shares. The overall ratings from various analysts show that one has rated the stock as a sell, two analysts have given it a hold rating, and three others have issued buy ratings. According to current data available on MarketBeat, the average rating for Inovio Pharmaceuticals is classified as "Hold," with a consensus target price of $12.40.

Institutional Holdings and Market Movements

Recently, several large investors have adjusted their holdings in Inovio Pharmaceuticals. Geode Capital Management LLC has increased its stake by 6.7% in the third quarter, now owning 621,631 shares valued at $3,594,000 after acquiring an additional 38,833 shares. Similarly, Barclays PLC inflated its shares by 282.6%, owning 34,003 shares worth $197,000, resulting from the purchase of an extra 25,116 shares. FMR LLC has also significantly raised its stake by 370.1%, owning 27,261 shares valued at $158,000 after buying an extra 21,462 shares.

Moreover, State Street Corp enhanced its holdings by 11.7%, now holding 490,662 shares worth $2,836,000 after acquiring more shares. Green Alpha Advisors LLC has also shown confidence in the stock by increasing its stake by 103.2% in the fourth quarter, owning 65,446 shares worth $120,000 after purchasing an additional 33,232 shares. Presently, institutional investors hold around 26.79% of Inovio Pharmaceuticals stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on creating DNA medicines to treat and prevent diseases linked to human papillomavirus (HPV), cancer, and infectious diseases. The company leverages its innovative DNA medicines platform, utilizing smart delivery technology and uniquely crafted SynCon DNA sequences to optimize target antigen treatment.

HC Wainwright, Inovio, Pharmaceuticals